Second Spring? Coverage Expansion Fuels Big Pharma China Growth But '4+7' Impact Lingers

 
• By Brian Yang

AstraZeneca, Novartis and Roche deliver north of 20% sales growth in China again, driven by expanded reimbursement coverage and new product launches, but some clouds are on the horizon over falling sales due to the impact of the expanding “4+7” centralized procurement scheme.

China growth
Big Pharma Sees Continued Strong China Growth • Source: Shutterstock

More from China

More from Focus On Asia